German-Korean biotech startup Koralo has announced an update regarding its ongoing research and development activities, alongside its broader operational expansion plans.

The company stated that it recently conducted a clinical study in the United States as part of its continued efforts to develop postbiotic-based ingredients using its proprietary co-fermentation technology. The research forms part of Koralo’s wider initiative to explore applications of fermentation-derived compounds across multiple sectors.

Koralo is currently operating a manufacturing base in Jeonju, South Korea, where it is leveraging local fermentation infrastructure to support its production and development processes. The facility is expected to play a role in the company’s planned expansion into international markets.

According to the company, its co-fermentation platform is being used to develop two product categories—one intended for human food applications and another for aquafeed. Both product lines are derived from a shared production approach, allowing for consistency across applications.

The company noted that its ingredients are designed for integration into a range of formats, including beverages, dairy products, baked goods, dietary supplements, and feed solutions. These developments are part of Koralo’s broader focus on ingredient innovation within the food and feed industries.

Koralo indicated that it is currently targeting the United States and South Korea for its food-related initiatives, while also exploring opportunities in Europe and Southeast Asia for aquafeed applications.

The company stated that it will continue to focus on research and development of fermentation-based ingredients, with ongoing efforts directed toward expanding its presence in global markets.

Media Contact

Organization: Koralo GmbH (Koralo Co., Ltd.)

Contact Person: Sina Albanese (CEO)

Website: http://www.koralo-foods.com/

Email: Send Email

Country:Korea South

Release id:44299

The post German-Korean Biotech Startup Koralo Announces Clinical Research Update and Expansion Strategy appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

Sarasota, Florida, United States, 27th Apr 2026 – Genoscience, a premier U.S. supplier of high-purity research peptides, announced it has received the 2026 Global Recognition Award. The company was honored for redefining institutional laboratory procurement through a secure supply chain built on domestic logistics, cGMP-compliant sourcing, and 99% analytical transparency.

Founded by Kristelle Dammarell, Genoscience entered a scientific supply market flooded with unverified importers. Historically, scientists sourcing Research Peptides in the U.S. frequently encountered reagents of uncertain origin, jeopardizing the reproducibility of complex in-vitro assays. Genoscience solved this structural failure by building a specialized procurement model. As a dedicated scientific supplier, the company ensures its entire inventory is manufactured under strict Current Good Manufacturing Practice (cGMP) regulations, guaranteeing uncompromising batch-to-batch consistency for longitudinal studies.

Today, when principal investigators are buying research peptides online, analytical verification is paramount. Operating on the principle of verifiable data, Genoscience mandates independent High-Performance Liquid Chromatography (HPLC) and mass spectrometry testing for every batch. This publicly available reporting ensures laboratories receive only High-Purity Research Peptides. Furthermore, Genoscience’s Sarasota-based fulfillment eliminates the risks of international customs delays, utilizing secure, climate-stable logistics to ensure lyophilized compounds arrive with their peptide bonds and structural conformations fully intact.

Beyond secure procurement, the company supports the scientific community through the Genoscience Hub. This dedicated educational platform equips researchers with detailed guides, stringent handling protocols, and advanced literature to prevent thermal degradation at the bench.

“The fidelity of your research data is entirely dependent on the quality of your reagents,” said Kristelle Dammarell, Founder of Genoscience. “We designed our domestic logistics network, our automated subscription model, and the Genoscience Hub around what principal investigators actually need: >99% verified purity, cGMP-sourced consistency, and uninterrupted supply continuity for their Research Peptides.”

The 2026 Global Recognition Award evaluated Genoscience’s operational excellence across six categories, utilizing the Rasch model to verify performance. The award corroborates the company’s commitment to equipping bench scientists with the precise, institutional-grade molecular tools required to execute highly reproducible structural biology and cellular bioenergetics research.

About Genoscience

Located in Sarasota, Florida, Genoscience is a leading institutional supplier of high-purity, HPLC-verified synthetic peptides and molecular probes. Dedicated exclusively to supporting advanced in-vitro laboratory analysis and research, Genoscience provides principal investigators with uncompromising analytical transparency, cGMP-compliant sourcing, and secure domestic logistics to ensure optimal experimental reproducibility. For more information, visit Genoscience.net.

Important Legal & Safety Notice: All compounds discussed are intended for in-vitro research and analytical use only. They are not approved for human or animal consumption. Researchers are solely responsible for ensuring their handling, reconstitution, and storage protocols meet all applicable institutional, ethical, and legal standards.

Media Contact

Organization: Genoscience

Contact Person: Kristelle Dammarell

Website: https://genoscience.net/

Email: Send Email

City: Sarasota

State: Florida

Country:United States

Release id:44387

The post Genoscience Wins 2026 Global Award for High-Purity Research Peptides appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

Protocol-Owned Markets, Contribution-Based Asset Ownership, Dual-Token Flywheel—VestaDAO Redefines Decentralized Finance
 

From the “liquidity mining” boom in 2020 to today’s TVL stabilizing above $130 billion, DeFi has expanded rapidly—but it has also exposed deep structural flaws: protocols rely on high rewards to “rent” liquidity, only to collapse when capital exits; governance tokens lack value anchoring and devolve into speculative instruments; ordinary users’ contributions cannot be properly recognized, leaving ecosystems dominated by whales. These problems are now being systematically addressed by a new-generation DeFi 5.0 platform: VestaDAO.

Protocol-Owned Liquidity: No More “Renting,” Becoming the Market Itself

Traditional DeFi protocols often pay high native token incentives to attract LPs. Once rewards decline, liquidity quickly disappears, creating fertile ground for “vampire attacks.” VestaDAO adopts a Protocol-Owned Liquidity (POL) mechanism, acquiring and permanently controlling LP assets through bond sales. All inflows are automatically split into treasury reserves and protocol-owned liquidity, and deployed through an AI-powered Stratified Liquidity System (SLS) into key value zones such as price floors, anti-dump ranges, and resistance bands, actively managing price stability.

This means: VestaDAO no longer “rents” liquidity—it is the market.

Dual-Token Separation Model: Ending the “Hold vs. Use” Dilemma
Many DeFi protocols face a trade-off: tokens used for governance are hard to use for payments, and tokens used for transactions struggle to store value. VestaDAO introduces an original dual-token model: VSD + DF5.

• VSD: An algorithmic non-stable coin backed by treasury assets, used for bonds, staking, ecosystem payments, and governance. Every VSD is supported by an equal or greater Risk-Free Value (RFV) from the treasury. • DF5: A contribution token with a total supply of 1 million and a final circulating supply of only 10,000. It is generated exclusively through invitation actions and the CVA contribution value algorithm. In early stages, it can only be sold (not bought) on the secondary market, with a one-sided sell mechanism and buyback support.

Together, they form a flywheel: staking VSD generates yield, while consuming DF5 accelerates reward release. As DF5 is continuously burned, its scarcity increases, feeding back into the VSD ecosystem. Users no longer need to choose between “holding for appreciation” and “spending for utility.”

Contribution Value Ownership: Every Action Becomes an Asset
VestaDAO upgrades traditional DeFi from a “capital-driven” model to a“capital + contribution dual-driven” system. Any action that contributes to ecosystem growth—inviting new users, long-term staking, social engagement, governance participation—is quantified through the CVA (Contribution Value Algorithm) and mapped into DF5 token rewards, released linearly over 365 days to encourage sustained participation.

Referral rewards can reach up to 160% of the staking value, distributed across 30 layers; community contribution rewards are settled daily in VSD; NFT membership card holders enjoy multiple layers of premium dividends. Here, every like, invite, and vote you make is converted into tangible assets.

The Engine of DeFi 5.0 Has Ignited
VestaDAO is incubated by top-tier institution Spartan Capital, with support from Binance Chain technical teams and resources tied to the London Stock Exchange. The year 2026 is widely seen as the beginning of “system-level application” breakthroughs, and VestaDAO positions itself as both a pioneer and a definer of this new era.

Following its mainnet launch, VSD staking offers compound yields of up to 3,000% APY, while DF5 contribution incentives are rapidly expanding across global communities. Whether you are an experienced DeFi participant or a newcomer to Web3, VestaDAO offers a fair starting line where “contribution equals reward.”

Join VestaDAO and help build a decentralized financial world that is free, fair, inclusive, and independent.

Media Contact

Organization: Vesta Dao

Contact Person: Jenny

Website: https://app.vestadao.finance

Email: Send Email

Country:United States

Release id:44405

The post VestaDAO Introduces Three Innovations to Break DeFi Liquidity Constraints appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section